<DOC>
	<DOCNO>NCT01665417</DOCNO>
	<brief_summary>This study design compare efficacy safety first-line icotinib treatment first-line chemotherapy follow maintenance treatment icotinib .</brief_summary>
	<brief_title>Icotinib First-line Maintenance Treatment EGFR Mutated Patients With Lung Adenocarcinoma</brief_title>
	<detailed_description>This study design compare efficacy safety first-line icotinib treatment first-line chemotherapy follow maintenance icotinib . Primary endpoint : Progression-free survival first-line icotinib treatment first-line chemotherapy follow maintenance icotinib Secondary endpoint : 1 . Overall survival icotinib chemotherapy 2 . Time Progression icotinib chemotherapy 3 . Objective response rate disease control rate icotinib chemotherapy</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Pathologic confirmation lung adenocarcinoma measurable disease , define least one lesion accurately measure least one dimension ( long diameter record CT ) ; Patients must previously untreated locally advanced metastatic NSCLC ; Patients must lung cancer document EGFR activate mutation ( exon 19 deletion , L858R ) . Prior chemotherapy Prior treatment gefitinib , erlotinib , drug target EGFR Patients must receive investigational agent Any evidence interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Icotinib</keyword>
	<keyword>EGFR positive mutation</keyword>
	<keyword>First-line treatment</keyword>
	<keyword>Maintenance treatment</keyword>
</DOC>